KLK3 and prostate cancer: In a noteworthy development, the U.S. Food and Drug Administration (FDA) recently approved PCAT-3 lncRNA as a biomarker for prostate cancer in urine, demonstrating higher sensitivity and specificity compared to the traditional prostate-specific antigen (PSA) blood test [42].